Company Aprogen Biologics Inc.

A003060

KR7003060001

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 2026-03-13			5-day change	1st Jan Change
272.00 ^KRW	-2.86%		-7.17%	-47.59%

Nov. 13	Aprogen Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-23	Aprogen Biologics Inc. announced that it has received KRW 15 billion in funding from APTN Inc.	CI

Business description: Aprogen Biologics Inc.

Aprogen Biologics Inc, formerly Aprogen Pharmaceuticals Inc, is a Korea-based company principally engaged in the pharmaceutical business. The Company operates its business through two segments. The Medicine Business segment is engaged in the manufacture and sale of central nervous system drugs, autonomic agents, arteriosclerosis agents, metabolic agents, circulatory system drugs, biopharmaceuticals and others. The Segment is also engaged in the manufacture and sale of cosmetics such as skin moisturizers and others. The Gaming Business segment is engaged in the development and operation of role-playing games (RPGs).

Number of employees: 391

Sales by Activity: Aprogen Biologics Inc.

Fiscal Period: December	2020 (KRW)	2021 (KRW)	2022 (KRW)	2023 (KRW)	2024 (KRW)
Pharmaceutical Business Division	50.8B	55.74B	64.74B	62.95B	57.57B
Bio Business Division	-	-	274M	16.87B	9.45B
Other Sales	-	-	-	812M	359M
Insulation Business Division	-	-	-	6.37B	-
Game Business Division	2.52B	738M	173M	358M	-

See all business segments

Geographical breakdown of sales: Aprogen Biologics Inc.

Fiscal Period: December	2020 (KRW)	2021 (KRW)	2022 (KRW)	2023 (KRW)	2024 (KRW)

See all geographic segments

Executive Committee: Aprogen Biologics Inc.

Manager	Title	Age	Since
Jae-Seob Kim CEO	Chief Executive Officer	63	2023-10-12
Jung-Chool Kim CEO	Chief Executive Officer	69	2012-03-31
Jong-Soo Kang SAM	Sales & Marketing	62	-
Young-Suk Yeom AUD	Comptroller/Controller/Auditor	51	-
Yun-Gyeong Bae CTO	Chief Tech/Sci/R&D Officer	62	-

See APROGEN BIOLOGICS INC. governance

Composition of the Board of Directors: Aprogen Biologics Inc.

Director	Title	Age	Since
Jae-Seob Kim BRD	Director/Board Member	63	2023-10-12
Jung-Chool Kim BRD	Director/Board Member	69	2012-03-31
Jong-Soo Kang BRD	Director/Board Member	62	-
Dong-Chul Shin BRD	Director/Board Member	65	2020-03-22

Composition of the Board of Directors

Shareholders: Aprogen Biologics Inc.

Name	Equities	%	Valuation
APROGEN MEDICINES INC. 56.87 %	112,830,917	56.87 %	26 M ₩
Joy New Technology Association No 61 4.536 %	9,000,000	4.536 %	2 M ₩
APROGEN BIOLOGICS INC. 0.4209 %	835,039	0.4209 %	190 406 ₩
Jung-Chool Kim 0.011 %	21,880	0.011 %	4 989 ₩
Sung Nao 0.006564 %	13,024	0.006564 %	2 970 ₩

List of APROGEN BIOLOGICS INC. shareholders

Holdings: Aprogen Biologics Inc.

Name	Equities	%	Valuation
APTOCROM INC. 18.24%	40,269,859	18.24%	5 M $
APROGEN BIOLOGICS INC. 0.42%	835,039	0.42%	190 406 $
APROGEN MEDICINES INC. -.--%	0	-.--%	- $

Company details: Aprogen Biologics Inc.

Aprogen Biologics, Inc.

Room 301, Gangho Building

05641, Seoul

http://www.aprogen-pharm.com

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
APROGEN BIOLOGICS INC.	-2.86%	-7.17%	-63.83%	-91.88%	37.13M
ELI LILLY AND COMPANY	+1.38%	+0.00%	+23.54%	+205.21%	873B
JOHNSON & JOHNSON	+0.33%	+1.14%	+49.17%	+58.85%	583B
ABBVIE INC.	-1.12%	-3.06%	+5.44%	+46.80%	398B
ROCHE HOLDING AG	+0.79%	-6.01%	+5.81%	+21.36%	324B
ASTRAZENECA PLC	+0.11%	-0.83%	+21.02%	+34.57%	297B
NOVARTIS AG	+0.43%	-1.54%	+25.20%	+62.42%	294B
MERCK & CO., INC.	+0.63%	+0.82%	+23.26%	+10.41%	287B
AMGEN INC.	-0.04%	-0.40%	+17.73%	+57.84%	198B
GILEAD SCIENCES, INC.	+0.77%	+1.14%	+28.43%	+83.09%	180B
Average	-0.04%	-1.99%	+13.58%	+48.87%	343.54B
Weighted average by Cap.	+0.42%	-1.74%	+23.94%	+86.48%